LUPIN (Lupin Ltd.): Buyback
Lupin Ltd. informed the exchange on 1 July 2026 that its subsidiary Multicare Pharmaceuticals Philippines, Inc. (MPPI) has completed a buyback of shares alongside the acquisition of minority shareholding in MPPI, according to the NSE filing. The disclosure, titled "Intimation – Completion of Acquisition & Buyback," was published at 18:18 on the same date.
Events like this have historically shown a 57.1% win rate across 42 comparable instances, with a net edge of 0.374%, according to Strota's base rate data. This means a majority of past buyback announcements have been followed by positive price movement, though the edge is modest and past performance does not indicate future results for this specific stock.
Lupin closed at ₹2,397.5 on 1 July 2026, down 0.89% from the previous session, while the Nifty rose 0.59%. The stock trades 3.87% below its 52-week high of ₹2,494 and 30.53% above its 52-week low of ₹1,836.8. Relative volume stood at 0.6, indicating below-average trading activity. The 14-day RSI reads 63.7, and the stock holds above both its 50-day and 200-day simple moving averages. Valuation metrics show a price-to-earnings ratio of 20.61 and return on equity of 26.9%.
The filing confirms the buyback completion but does not disclose the size, pricing, or number of shares repurchased. The data establishes that the announcement occurred and that similar events have historically tilted slightly positive, not that this stock will follow that pattern.
The catalyst
Lupin Limited has informed the Exchange about update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary company and Buyback of shares by MPPI. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Buyback tends to continue — the move went bullish in about 57.1% of next sessions (net 0.374% after drift and cost, n=42). A base rate, not a forecast for this stock.
LUPIN right now
trading -0.89% on the day; P/E 20.61; RSI 63.7. Full LUPIN analysis →
Sources
- Lupin Limited has informed the Exchange about update on acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary company and Buyback of shares by MPPI. — NSE
- Bharat Electronics, NTPC, Lupin: Top stocks to buy — Check price targets, stop loss & more — Business Today
- Neutral Lupin Ltd for the Target Rs.2,520 by Motilal Oswal Financial Services Ltd — Investment Guru India
- Lupin Q4 PAT jumps 87.7 pc to Rs 1,468.7 cr — ETPharma.com
- Lupin Exceeds Q4 Revenue Estimates; Guides for Billion-Dollar-Plus US Sales in FY27 — IndiaMedToday
Keep digging
- LUPIN — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.